Shares of Cellectar Biosciences, Inc. (NASDAQ:CLRB – Get Free Report) have been given an average rating of “Moderate Buy” by the five brokerages that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $11.00.
CLRB has been the subject of several recent analyst reports. Wall Street Zen downgraded shares of Cellectar Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Cellectar Biosciences in a report on Thursday, October 15th.
Get Our Latest Report on Cellectar Biosciences
Cellectar Biosciences Price Performance
Shares of CLRB stock opened at $1.14 on Monday. Cellectar Biosciences has a 12 month low of $1.11 and a 12 month high of $4.70. The business’s 50 day moving average is $1.63 and its two-hundred day moving average is $2.52. The company has a market cap of $11.45 million, a PE ratio of -0.39 and a beta of 0.65.
Cellectar Biosciences (NASDAQ:CLRB – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.10. As a group, equities analysts expect that Cellectar Biosciences will post -2.31 EPS for the current fiscal year.
Cellectar Biosciences Company Profile
Cellectar Biosciences, Inc. is a clinical-stage biotechnology company focused on developing targeted radiopharmaceuticals for cancer. Its proprietary phospholipid ether (PLE) platform is designed to help compounds selectively accumulate in cancer cells. The company’s lead investigational program is iopofosine I 131, also known as CLR 131, a radiotherapeutic that uses iodine-131 to deliver radiation to cancer cells. Cellectar has studied the candidate in multiple myeloma and other blood cancers. Cellectar’s research and development activities also include other programs based on its PLE platform.
See Also
- Five stocks we like better than Cellectar Biosciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Cellectar Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
